Evidence map›Paper›PMID 20501597›Full record

ArticleEuropean journal of endocrinology2010

Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity.

D J Brick, A V Gerweck, E Meenaghan, E A Lawson, M Misra, P Fazeli, W Johnson, A Klibanski, K K Miller

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in European journal of endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03610412 (Effect of Cinnamomum Cassia as an Enhancer of the Insulin Response of the Insulin-Like Growth Factor-1 and Metabolic Control in Patients With Type 2 Diabetes Mellitus Treated With Metformin Without Glycemic Control), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03610412 phase3completednot on this mapstarted 2019, after this paper: background citation

Effect of Cinnamomum Cassia as an Enhancer of the Insulin Response of the Insulin-Like Growth Factor-1 and Metabolic Control in Patients With Type 2 Diabetes Mellitus Treated With Metformin Without Glycemic Control

TypeinterventionalSponsorCoordinación de Investigación en Salud, MexicoRan2019 to 2021Enrolled28ConditionsDiabetes Mellitus, Type 2ArmsCinnamomum Cassia, Placebo (calcined magnesia)
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
  5. Article
  6. Role of Obesity in the Tumorigenesis of Gastric Cancer.International journal of preventive medicine · 2020
    Review
  7. Review
  8. Neuroactive Steroids and Affective Symptoms in Women Across the Weight Spectrum.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Determinants of GH resistance in malnutrition.The Journal of endocrinology · 2014
    Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

D J BrickDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
A V Gerweck
E Meenaghan
E A Lawson
M Misra
P Fazeli
W Johnson
A Klibanski
K K Miller
Massachusetts General Hospital · USMass General Brigham · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI HOGE, ELIZABETH A · 1985 to 2008
$37.4M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Alessio Fasano · 1994 to 2026
$31.6M
GH, Cardiovascular Risk and Visceral Adiposity in WomenR01HL077674 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · 2007 to 2011
$3.2M
Growth Hormone and Cardiovascular DiseaseK24HL092902 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · 2010 to 2019
$1.6M
NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR01066NCRR NIH HHS UL1 RR025758NHLBI NIH HHS K24 HL092902NHLBI NIH HHS R01 HL077674NIDDK NIH HHS P30 DK040561NIDDK NIH HHS R01 DK52525
6 · The paper itself

Abstract

contextChronic starvation is characterized by GH resistance, and obesity is characterized by decreased GH secretion. In both extremes, IGF1 levels may be low and androgen levels may be abnormal.

objectiveTo investigate the determinants of IGF1 and GH across the weight spectrum in women.

designCross-sectional study.

settingClinical research center. STUDY

participantsIn total, 32 women had participated in the study: 11 women with anorexia nervosa (AN), 11 normal-weight women, and 10 obese women of comparable mean age.

interventionNone.

main outcome measuresPooled hourly overnight serum samples assayed for IGF1, GH, estradiol (E(2)), testosterone, SHBG, insulin, free fatty acids, and trunk fat.

resultsFree testosterone was higher in obese women and lower in women with AN than in normal-weight women, and was the only independent (and positive) predictor of IGF1 levels, accounting for 14% of the variability (P=0.032) in the group as a whole. This relationship was stronger when obese women were excluded, with free testosterone accounting for 36% of the variability (P=0.003). Trunk fat accounted for 49% of the variability (P<0.0001) of GH, with an additional 7% of the variability attributable to E(2) (P=0.042) in the group as a whole, but was not a significant determinant of GH secretion when obese women were excluded.

conclusionsFree testosterone is a significant determinant of IGF1 levels in women across the body weight spectrum. In contrast, GH secretion is differentially regulated at the extremes of the weight spectrum.

Indexed as

Adipose TissueAdolescentAnorexia NervosaBody CompositionBody Mass IndexBody WeightCross-Sectional StudiesEstradiolFatty Acids, NonesterifiedFemaleHuman Growth HormoneHumansInsulinInsulin-Like Growth Factor IMiddle AgedObesityEstradiolFatty Acids, NonesterifiedHuman Growth HormoneInsulinInsulin-Like Growth Factor ISex Hormone-Binding GlobulinTestosterone

Identifiers

PMID20501597
PMCPMC2953770
OpenAlexW2165655868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.